Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Multimodal framework for the joint analysis of single-cell RNA and T cell receptor sequencing data predicts T cell response to cancer immunotherapy.

  PMID 41820396 · PMC13121706 · Nature communications · 2026 · 8 claims · 7 setups

  Full-text index only

  TRIM, a conditional multi-modal variational autoencoder integrating paired scRNAseq and scTCRseq data, predicts T cell clonality and transcriptional states at unmeasured tissue sites/timepoints.

  hnscc colorectal pan-cancer tcr paired umap convolutional

• Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.

  PMID 41855504 · PMC13234471 · Blood advances · 2026 · 8 claims · 7 setups

  Full-text index only

  LiP-Seq is a novel platform combining multiplexed live-cell imaging and needle-based single-cell retrieval that enables transcriptomic profiling of ultrarare (down to 10^-6 frequency), viable persistent lymphoma cells

  mcl longitudinal scrna-seq pbmc live-cell sort-seq scrna-seq

• Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy.

  PMID 41758930 · PMC13197979 · Blood · 2026 · 8 claims · 6 setups

  Full-text index only

  Orca-T immunotherapy leads to increased phenotypic T-cell activation compared with unmanipulated PBSC grafts, persisting for months after treatment.

  peripheral sorted fresh cryopreserved flow single-cell tcr

• Pre-existing cell states predict resistance to multiple treatments.

  PMID 41916275 · PMC13261651 · Cell genomics · 2026 · 8 claims · 5 setups

  Full-text index only

  Rare melanoma clones can develop resistance to multiple diverse treatments simultaneously, not just single treatments

  wm989 time-lapse barcode single-cell

• Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.

  PMID 41484081 · PMC12858953 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  Combined low-dose CTX + anti-CSF-1R (SNDX-ms6352) is highly effective against aggressive metastatic Trp53-null TNBC models with high macrophage infiltration, producing complete tumor regression in claudin-low models.

  trp53-null complete t12 cell-deficient imaging survival tumor